Bone marrow transplantation in accelerated chronic granulocytic leukaemia using dibromomannitol-preconditioning instead of total-body irradiation

Endre Kelemen, Margit Janossa, Éva Triska, Ferenc Szalay, András Váradi, Tamás Magyar, Mihály Sellyei

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In a preliminary study on five patients with accelerated CGL, transplantation of allogeneic matched bone marrow was shown to be feasible without whole-body irradiation. Animal experiments and studies with cells cultured in vitro suggest that the cytocastic drug used to kill leukaemic clones (Myelobromol-Chinoin) does not injure haemopoietic stroma. The administration of this protocol is cheap and easy. Our preconditioning does not, in itself, eradicate the malignant CGL clone immediately : 15-20% of marrow mitoses were Ph1+ one month after transplantation. For this reason, additional cytostatic therapy was given in the course of the 3rd to 6th post-transplant months. No Ph1+ cells were observed from the fourth post-transplant month onwards. Very few severe acute complications were seen and two out of three matched transplanted patients are disease-free 27 + and 13 + months later. On the basis of the developing normal spleen architecture and the changing pattern of circulating NAP score values, particularly the months-long persistence of distinctly low scores, and then the delayed emergence of normal levels, we put forward a hypothesis, emphasizing the role of environmental factors, including the formation of a normal haemopoietic stroma in the successfully transplanted CGL patient.

Original languageEnglish
Pages (from-to)1009-1015
Number of pages7
JournalLeukemia Research
Volume9
Issue number8
DOIs
Publication statusPublished - 1985

Fingerprint

Mitobronitol
Whole-Body Irradiation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Clone Cells
Bone Marrow
Transplants
Homologous Transplantation
Cytostatic Agents
Mitosis
Cultured Cells
Spleen
Transplantation
Pharmaceutical Preparations

Keywords

  • -post-transplant
  • Accelerated chronic granulocytic leukaemia
  • bone marrow transplantation without total-body irradiation
  • dibromomannitol (Myelobromol)
  • neutrophil alkaline phosphatase
  • Philadelphia chromosome
  • splenectomy
  • stroma -haemopoietic

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Bone marrow transplantation in accelerated chronic granulocytic leukaemia using dibromomannitol-preconditioning instead of total-body irradiation. / Kelemen, Endre; Janossa, Margit; Triska, Éva; Szalay, Ferenc; Váradi, András; Magyar, Tamás; Sellyei, Mihály.

In: Leukemia Research, Vol. 9, No. 8, 1985, p. 1009-1015.

Research output: Contribution to journalArticle

@article{7e2f51d6d73c4671b3767ac158f4a2dd,
title = "Bone marrow transplantation in accelerated chronic granulocytic leukaemia using dibromomannitol-preconditioning instead of total-body irradiation",
abstract = "In a preliminary study on five patients with accelerated CGL, transplantation of allogeneic matched bone marrow was shown to be feasible without whole-body irradiation. Animal experiments and studies with cells cultured in vitro suggest that the cytocastic drug used to kill leukaemic clones (Myelobromol-Chinoin) does not injure haemopoietic stroma. The administration of this protocol is cheap and easy. Our preconditioning does not, in itself, eradicate the malignant CGL clone immediately : 15-20{\%} of marrow mitoses were Ph1+ one month after transplantation. For this reason, additional cytostatic therapy was given in the course of the 3rd to 6th post-transplant months. No Ph1+ cells were observed from the fourth post-transplant month onwards. Very few severe acute complications were seen and two out of three matched transplanted patients are disease-free 27 + and 13 + months later. On the basis of the developing normal spleen architecture and the changing pattern of circulating NAP score values, particularly the months-long persistence of distinctly low scores, and then the delayed emergence of normal levels, we put forward a hypothesis, emphasizing the role of environmental factors, including the formation of a normal haemopoietic stroma in the successfully transplanted CGL patient.",
keywords = "-post-transplant, Accelerated chronic granulocytic leukaemia, bone marrow transplantation without total-body irradiation, dibromomannitol (Myelobromol), neutrophil alkaline phosphatase, Philadelphia chromosome, splenectomy, stroma -haemopoietic",
author = "Endre Kelemen and Margit Janossa and {\'E}va Triska and Ferenc Szalay and Andr{\'a}s V{\'a}radi and Tam{\'a}s Magyar and Mih{\'a}ly Sellyei",
year = "1985",
doi = "10.1016/0145-2126(85)90071-2",
language = "English",
volume = "9",
pages = "1009--1015",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Bone marrow transplantation in accelerated chronic granulocytic leukaemia using dibromomannitol-preconditioning instead of total-body irradiation

AU - Kelemen, Endre

AU - Janossa, Margit

AU - Triska, Éva

AU - Szalay, Ferenc

AU - Váradi, András

AU - Magyar, Tamás

AU - Sellyei, Mihály

PY - 1985

Y1 - 1985

N2 - In a preliminary study on five patients with accelerated CGL, transplantation of allogeneic matched bone marrow was shown to be feasible without whole-body irradiation. Animal experiments and studies with cells cultured in vitro suggest that the cytocastic drug used to kill leukaemic clones (Myelobromol-Chinoin) does not injure haemopoietic stroma. The administration of this protocol is cheap and easy. Our preconditioning does not, in itself, eradicate the malignant CGL clone immediately : 15-20% of marrow mitoses were Ph1+ one month after transplantation. For this reason, additional cytostatic therapy was given in the course of the 3rd to 6th post-transplant months. No Ph1+ cells were observed from the fourth post-transplant month onwards. Very few severe acute complications were seen and two out of three matched transplanted patients are disease-free 27 + and 13 + months later. On the basis of the developing normal spleen architecture and the changing pattern of circulating NAP score values, particularly the months-long persistence of distinctly low scores, and then the delayed emergence of normal levels, we put forward a hypothesis, emphasizing the role of environmental factors, including the formation of a normal haemopoietic stroma in the successfully transplanted CGL patient.

AB - In a preliminary study on five patients with accelerated CGL, transplantation of allogeneic matched bone marrow was shown to be feasible without whole-body irradiation. Animal experiments and studies with cells cultured in vitro suggest that the cytocastic drug used to kill leukaemic clones (Myelobromol-Chinoin) does not injure haemopoietic stroma. The administration of this protocol is cheap and easy. Our preconditioning does not, in itself, eradicate the malignant CGL clone immediately : 15-20% of marrow mitoses were Ph1+ one month after transplantation. For this reason, additional cytostatic therapy was given in the course of the 3rd to 6th post-transplant months. No Ph1+ cells were observed from the fourth post-transplant month onwards. Very few severe acute complications were seen and two out of three matched transplanted patients are disease-free 27 + and 13 + months later. On the basis of the developing normal spleen architecture and the changing pattern of circulating NAP score values, particularly the months-long persistence of distinctly low scores, and then the delayed emergence of normal levels, we put forward a hypothesis, emphasizing the role of environmental factors, including the formation of a normal haemopoietic stroma in the successfully transplanted CGL patient.

KW - -post-transplant

KW - Accelerated chronic granulocytic leukaemia

KW - bone marrow transplantation without total-body irradiation

KW - dibromomannitol (Myelobromol)

KW - neutrophil alkaline phosphatase

KW - Philadelphia chromosome

KW - splenectomy

KW - stroma -haemopoietic

UR - http://www.scopus.com/inward/record.url?scp=0021971029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021971029&partnerID=8YFLogxK

U2 - 10.1016/0145-2126(85)90071-2

DO - 10.1016/0145-2126(85)90071-2

M3 - Article

C2 - 3930887

AN - SCOPUS:0021971029

VL - 9

SP - 1009

EP - 1015

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -